	US 12,297,253 B2
	Multi-domain immunomodulatory proteins and methods of use thereof
Ryan Swanson, Seattle, WA (US)
Assigned to Alpine Immune Sciences, Inc., Seattle, WA (US)
Appl. No. 16/959,662
Filed by Alpine Immune Sciences, Inc., Seattle, WA (US)
PCT Filed Jan. 3, 2019, PCT No. PCT/US2019/012222 § 371(c)(1), (2) Date Jul. 1, 2020, PCT Pub. No. WO2019/136179, PCT Pub. Date Jul. 11, 2019.
Claims priority of provisional application 62/733,622, filed on Sep. 19, 2018.
Claims priority of provisional application 62/613,378, filed on Jan. 3, 2018.
Prior Publication US 2023/0101432 A1, Mar. 30, 2023
Int. Cl. C07K 14/705 (2006.01); A61K 39/395 (2006.01); A61P 37/02 (2006.01); C07K 16/28 (2006.01); C07K 16/46 (2006.01)

CPC C07K 14/70532 (2013.01) [C07K 16/2896 (2013.01); C07K 16/461 (2013.01); C07K 2319/30 (2013.01)]

37 Claims

1. An immunomodulatory polypeptide comprising,

an activating receptor binding molecule (ARBM), wherein the ARBM comprises a variant CTLA-4 polypeptide comprising an L63P amino acid modification, wherein the variant CTLA-4 polypeptide amino acids are numbered with reference to SEQ ID NO: 36; and

an inhibitory receptor binding molecule (IRBM), wherein the IRBM comprises a variant PD-L1 polypeptide comprising an N45D amino acid modification, wherein the variant PD-L1 polypeptide amino acids are numbered with reference to SEQ ID NO: 309.